Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL

NCT07724782 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

PTCL-NOS

Interventions

DRUG: Zeprumetostat( an EZH2 inhibitor) + X

Sponsor

Tianjin Medical University Cancer Institute and Hospital